Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
|Videos|August 31, 2020
What quality registry data reveal about urethral stricture treatment
Andrew J. Cohen, MD, discusses a recent study evaluating treatment of urethral stricture disease in the US.
Advertisement
Andrew J. Cohen, MD, assistant professor of urology at Johns Hopkins University, regarding a recently published study in Urology titled “Significant Management Variability of Urethral stricture Disease in United States: Data from the AUA Quality (AQUA) Registry.” Cohen says the study provides “a small glimpse into the truly enormous research potential of the AUA Quality Registry.”
Advertisement
Related to this article
The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Topline results are expected in November 2026 ahead of a planned sBLA submission.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
Topline results from the study are anticipated in the first half of 2027.
Advertisement
Advertisement
Trending on Urology Times
1
Factors shaping PSMA-PET agent selection in prostate cancer
2
Nogapendekin alfa inbakicept plus BCG advances to final analysis in BCG-naïve NMIBC
3
Chad Ritch, MD, on using PSMA-PET to guide treatment decisions
4
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
5